3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Cystic Neoplasm
1
Malignant Liver Neoplasm
1
Liver Diseases
1
Carcinoma, Hepatocellular
1
Bone Cancer Metastatic
1
Interventions
Bevacizumab
69
atezolizumab
54
durvalumab
43
lenvatinib
42
Nivolumab
38
pembrolizumab
35
tremelimumab
29
Magnetic Resonance Spectroscopy
21
Specimen Handling
19
tislelizumab
18
sintilimab
17
Ipilimumab
15
Sorafenib
14
regorafenib
13
cabozantinib
13
Radiosurgery
13
Radiotherapy
12
apatinib
11
Blood Specimen Collection
11
Immunoglobulin G
10
camrelizumab
9
Immune Checkpoint Inhibitors
9
Disulfides
9
X-Rays
8
Cyclophosphamide
8
donafenib
7
Oxaliplatin
7
Immunotherapy
7
Folfox protocol
7
Fluorouracil
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Catheter Ablation
×
1 year
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled